Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.49 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177379 | 0.91 | GAA (0.56) | ALDH1A1PKMHTTTRPC3TRPC6 | |
| SCHEMBL4180264 | 0.89 | CCR3 (0.42) | ALDH1A1PKMGAAKMT2AMEN1 | |
| SCHEMBL4172986 | 0.87 | ALDH1A1 (0.46) | ALDH1A1PKMHTTTRPC3TRPC6 | |
| SCHEMBL4176363 | 0.86 | TACR3 (0.47) | ALDH1A1TRPC3TRPC6KMT2AMEN1 | |
| SCHEMBL4177020 | 0.86 | TRPC3 (0.51) | ALDH1A1PKMHTTTRPC3TRPC6 | |
| SCHEMBL4177775 | 0.86 | ALDH1A1 (0.41) | ALDH1A1PKMHTTTRPC3TRPC6 | |
| SCHEMBL4176042 | 0.86 | ALDH1A1 (0.47) | ALDH1A1PKMHTTTRPC3TRPC6 | |
| SCHEMBL4171049 | 0.85 | ALDH1A1 (0.43) | ALDH1A1PKMHTTTDP1GAA | |
| SCHEMBL4173029 | 0.84 | HCRTR1 (0.55) | ALDH1A1PKMHTTTRPC3TRPC6 | |
| SCHEMBL3162739 | 0.84 | GAA (0.42) | ALDH1A1PKMTDP1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | ALDH1A1 3113/4885PKM 2728/4885HTT 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.